CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy targets Hard-to-Treat stomach cancers in Mid-Stage trial
Disease control OngoingThis phase II trial is testing whether adding chemotherapy to the immunotherapy drug atezolizumab works better than atezolizumab alone for patients with a specific genetic type of stomach or gastroesophageal junction cancer (MSI-H/dMMR). The study involves 240 adults with localiz…
Matched conditions: CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 23, 2026 11:59 UTC
-
Chemotherapy delivered directly to the belly for stomach cancer
Disease control OngoingThis early-phase trial tests the safety and best dose of the chemotherapy drug paclitaxel when given directly into the abdomen (intraperitoneal) for people with advanced stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen. About 27 participant…
Matched conditions: CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 22, 2026 12:00 UTC
-
New combo therapy targets Hard-to-Treat stomach cancer
Disease control OngoingThis early-phase trial is testing whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy can help control gastroesophageal cancer that cannot be removed by surgery. The study includes 16 participants and primarily looks at safety and whether the cancer …
Matched conditions: CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 22, 2026 11:59 UTC
-
New combo therapy aims to wipe out esophageal cancer before surgery
Disease control OngoingThis early-phase trial tests whether giving chemoradiation plus the immunotherapy drug pembrolizumab, followed by pembrolizumab and lenvatinib before surgery, can kill more cancer cells in people with esophageal or gastroesophageal junction cancer that hasn't spread. The study in…
Matched conditions: CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 18, 2026 11:50 UTC
-
Immunotherapy combo shows promise in esophageal cancer trial
Disease control TerminatedThis study looks at whether adding two immunotherapy drugs, nivolumab and ipilimumab, to standard chemotherapy and radiation helps people with esophageal or gastroesophageal junction cancer before and after surgery. About 278 adults with stage II to IVA cancer will take part. The…
Matched conditions: CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
Immuno-Chemo-Radiation cocktail shows promise against stomach cancer
Disease control OngoingThis study tests whether giving two immunotherapy drugs (nivolumab and ipilimumab) along with chemotherapy and radiation before surgery can help treat stomach cancer that can be surgically removed. The trial includes 32 adults with early-stage stomach or gastroesophageal junction…
Matched conditions: CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC
-
Experimental combo targets Hard-to-Treat esophageal cancer
Disease control OngoingThis early-stage trial tested a drug called adavosertib together with radiation therapy for people with advanced esophageal or stomach cancer that cannot be surgically removed. The goal was to find the safest dose and see how well the combination works. Only 4 people took part, s…
Matched conditions: CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 09, 2026 12:06 UTC